# US 2014/0154261 A1 · Pharmaceutical composition for treatment and/or prophylaxis of cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154261 A1 - Document ID: US20140154261A1 - Status: Published application - Kind: A1 - Application number: 14/236,859 - Filed: 2012-08-03 - Published: 2014-06-05 - Earliest claimed: 2011-08-04 - Assignees: Toray Industries, Inc. - Inventors: Fumiyoshi Okano; Shinichi Kobayashi; Yoshitaka Minamida; Takanori Saito - Web page: https://patentgrep.com/patent/US20140154261A1 ## CPC - C07K 16/18: against material from animals or humans - A61K 39/39558: {against tumor tissues, cells, antigens} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - C07K 16/30: from tumour cells - A61K 2039/505: {comprising antibodies} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC] - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11. ## Claims ### Claim 1 An antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9, 10, and 11. ### Claim 2 (depends on 1) The antibody or the fragment thereof according to claim 1, wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a multispecific antibody. ### Claim 3 (depends on 1) The antibody or the fragment thereof according to claim 1, wherein the antibody or the fragment thereof is conjugated with an antitumor agent. ### Claim 4 (depends on 1) A pharmaceutical composition for treatment and/or prevention of cancer, comprising an antibody or a fragment thereof according to claim 1 as an active ingredient. ### Claim 5 (depends on 4) The pharmaceutical composition according to claim 4, wherein the cancer is breast cancer, kidney cancer, pancreatic cancer, large bowel cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma. ### Claim 6 (depends on 4) A pharmaceutical combination for treatment and/or prevention of cancer, comprising a pharmaceutical composition according to claim 4 and a pharmaceutical composition comprising an antitumor agent. ### Claim 7 (depends on 1) A DNA encoding an antibody or a fragment thereof according to claim 1. ### Claim 8 (depends on 1) A method for treating and/or preventing cancer, comprising administering an antibody or a fragment thereof according to claim 1. ### Claim 9 (depends on 2) The antibody or the fragment thereof according to claim 2, wherein the antibody or the fragment thereof is conjugated with an antitumor agent. ### Claim 10 (depends on 2) A pharmaceutical composition for treatment and/or prevention of cancer, comprising an antibody or a fragment thereof according to claim 2 as an active ingredient. ### Claim 11 (depends on 3) A pharmaceutical composition for treatment and/or prevention of cancer, comprising an antibody or a fragment thereof according to claim 3 as an active ingredient. ### Claim 12 (depends on 5) A pharmaceutical combination for treatment and/or prevention of cancer, comprising a pharmaceutical composition according to claim 5 and a pharmaceutical composition comprising an antitumor agent. ### Claim 13 (depends on 2) A DNA encoding an antibody or a fragment thereof according to claim 2. ### Claim 14 (depends on 4) A method for treating and/or preventing cancer, comprising administering an antibody or a fragment thereof according to claim 4. ### Claim 15 (depends on 6) A method for treating and/or preventing cancer, comprising administering an antibody or a fragment thereof according to claim 6.